Most ferroptosis-inducing agents discussed in this section—including natural products, HO-1 inhibitors, GPX4 antagonists, and nanotechnology-based carriers—remain at the preclinical stage with no clinical trials yet conducted in NPC. This evidence concerns the gene GPX4 and nasopharyngeal carcinoma.